InnoCare Pharma Limited

InnoCare Pharma Limited (HKEX: 9969; SSE: 688428) is a commercial-stage biopharmaceutical company headquartered in Beijing, China, founded in 2015 and dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. The company has built a fully integrated biopharma platform encompassing drug discovery, clinical development, manufacturing, and commercialization, with three approved drugs — Orelabrutinib (a BTK inhibitor), Tafasitamab, and Zurletrectinib — as well as more than ten innovative drug candidates in clinical development targeting hematological tumors, solid tumors, and autoimmune diseases. Orelabrutinib, InnoCare's flagship product, has received marketing approval in China and Singapore and has been included in China's National Reimbursement Drug List (NRDL), while the company's broader pipeline features assets such as ICP-192 (a pan-FGFR inhibitor), ICP-332 (a TYK2 inhibitor), and ICP-723 (a pan-TRK inhibitor), among others. With approximately 1,089 full-time employees and a market capitalization of approximately USD 2.3 billion, InnoCare operates across multiple locations including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, reflecting its ambition to become a global biopharmaceutical leader.